Back to top

Surging Earnings Estimates Signal Good News for Nektar (NKTR)

Read MoreHide Full Article

Nektar Therapeutics (NKTR - Free Report) is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on NKTR’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Nektar could be a solid choice for investors.

Current Quarter Estimates for NKTR

In the past 30 days, three estimates have gone higher for Nektar while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from a loss of 7 cents a share 30 days ago, to earnings of 21 cents today.

Current Year Estimates for NKTR

Meanwhile, Nektar’s current year figures are also looking quite promising, with two estimates moving higher in the past month, compared to one lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.08 per share 30 days ago to a loss of $1.05 per share today, an increase of 2.8%.

Nektar Therapeutics Price and Consensus

Bottom Line

The stock has also started to move higher lately, adding 16% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Nektar Therapeutics (NKTR) - free report >>

More from Zacks Tale of the Tape

You May Like